mAbxience Chooses Genedata Bioprocess to Streamline CDMO Operations for Enhanced Efficiency mAbxience partners with Genedata to leverage innovative software for automating biopharmaceutical workflows, improving operational efficiency and data integrity.

mAbxience Chooses Genedata Bioprocess to Streamline CDMO Operations for Enhanced Efficiency #Switzerland #Biopharmaceutical #Basel #mAbxience #Genedata

mAbxience and HP Collaborate on Innovative AI Solutions in Biomanufacturing mAbxience and HP Inc. are pioneering artificial intelligence applications in biomanufacturing. This collaboration aims to enhance efficiency and improve production of monoclonal antibodies.

mAbxience and HP Collaborate on Innovative AI Solutions in Biomanufacturing #USA #Madrid #Biomanufacturing #mAbxience #HP_Inc

mAbxience Achieves Milestone with European Approval for Denosumab Biosimilars mAbxience proudly announces the European Commission's approval of its denosumab biosimilars, Denbrayce® and Izamby®, enhancing access to critical therapies.

mAbxience Achieves Milestone with European Approval for Denosumab Biosimilars #Spain #Madrid #Fresenius_Kabi #Denosumab #mAbxience

mAbxience Celebrates European Commission Approval for Denosumab Biosimilars mAbxience announces that the European Commission has approved its Denosumab biosimilars, promising improved access to critical therapies across Europe.

mAbxience Celebrates European Commission Approval for Denosumab Biosimilars #Spain #Madrid #Fresenius_Kabi #Denosumab #mAbxience

mAbxience Attains European Commission Approval for Denosumab Biosimilars Denbrayce and Izamby mAbxience has received European Commission approval for its biosimilars Denbrayce and Izamby, marking a significant advancement in accessible healthcare.

mAbxience Attains European Commission Approval for Denosumab Biosimilars Denbrayce and Izamby #Spain #Madrid #mAbxience #Denbrayce #Izamby

mAbxience Receives European Commission Approval for Denosumab Biosimilars The European Commission has approved mAbxience’s biosimilars for denosumab, indicating a significant milestone in providing accessible therapies across Europe.

mAbxience Receives European Commission Approval for Denosumab Biosimilars #Spain #Madrid #mAbxience #Denbrayce #Izamby

mAbxience Celebrates European Commission Approval of Denosumab Biosimilars for Patients mAbxience announces significant progress with the European Commission's approval of its denosumab biosimilars, Denbrayce® and Izamby®, enhancing patient access to essential therapies.

mAbxience Celebrates European Commission Approval of Denosumab Biosimilars for Patients #Spain #Madrid #Healthcare_Access #Denosumab_Biosimilars #mAbxience